Improving intermediate risk classification of prostate cancer with radiomics features

2021 ◽  
Vol 79 ◽  
pp. S1309
Author(s):  
R. Thenault ◽  
L. Beuzit ◽  
N. Rioux-Leclercq ◽  
Z-E. Khene ◽  
A. Gasmi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Classification ◽  
Intermediate Risk

Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer

2012 ◽  
Vol 29 (4) ◽  
pp. 2895-2900 ◽  
Author(s):  
Akinori Minato ◽  
Naohiro Fujimoto ◽  
Tatsuhiko Kubo ◽  
Shuji Harada ◽  
Soichiro Akasaka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Classification ◽  
Estramustine Phosphate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors

2021 ◽  
Vol 11 ◽  
Author(s):  
Haijia Mao ◽  
Bingqian Zhang ◽  
Mingyue Zou ◽  
Yanan Huang ◽  
Liming Yang ◽  
...  
Keyword(s):  
High Risk ◽  
Random Forest ◽  
Gastrointestinal Stromal Tumors ◽  
Roc Curves ◽  
Risk Classification ◽  
Low Risk ◽  
Intermediate Risk ◽  
Stromal Tumors ◽  
Mr Sequences

BackgroundWe conduct a study in developing and validating four MRI-based radiomics models to preoperatively predict the risk classification of gastrointestinal stromal tumors (GISTs).MethodsForty-one patients (low-risk = 17, intermediate-risk = 13, high-risk = 11) underwent MRI before surgery between September 2013 and March 2019 in this retrospective study. The Kruskal–Wallis test with Bonferonni correction and variance threshold was used to select appropriate features, and the Random Forest model (three classification model) was used to select features among the high-risk, intermediate-risk, and low-risk of GISTs. The predictive performance of the models built by the Random Forest was estimated by a 5-fold cross validation (5FCV). Their performance was estimated using the receiver operating characteristic (ROC) curve, summarized as the area under the ROC curve (AUC). Area under the curve (AUC), accuracy, sensitivity, and specificity for risk classification were reported. Linear discriminant analysis (LDA) was used to assess the discriminative ability of these radiomics models.ResultsThe high-risk, intermediate-risk, and low-risk of GISTs were well classified by radiomics models, the micro-average of ROC curves was 0.85, 0.81, 0.87 and 0.94 for T1WI, T2WI, ADC and combined three MR sequences. And ROC curves achieved excellent AUCs for T1WI (0.85, 0.75 and 0.82), T2WI (0.69, 0.78 and 0.78), ADC (0.85, 0.77 and 0.80) and combined three MR sequences (0.96, 0.92, 0.81) for the diagnosis of high-risk, intermediate-risk, and low-risk of GISTs, respectively. In addition, LDA demonstrated the different risk of GISTs were correctly classified by radiomics analysis (61.0% for T1WI, 70.7% for T2WI, 83.3% for ADC, and 78.9% for the combined three MR sequences).ConclusionsRadiomics models based on a single sequence and combined three MR sequences can be a noninvasive method to evaluate the risk classification of GISTs, which may help the treatment of GISTs patients in the future.

850: Contemporary Evaluation of the D'amico Risk Classification of Prostate Cancer (PCA)

2007 ◽  
Vol 177 (4S) ◽  
pp. 284-284
Author(s):  
David J. Hernandez ◽  
Matthew E. Nielsen ◽  
Alan W. Partin ◽  
Misop Han
Keyword(s):  
Prostate Cancer ◽  
Risk Classification

Contemporary Evaluation of the D’Amico Risk Classification of Prostate Cancer

Urology ◽  
2007 ◽  
Vol 70 (5) ◽  
pp. 931-935 ◽  
Author(s):  
David J. Hernandez ◽  
Matthew E. Nielsen ◽  
Misop Han ◽  
Alan W. Partin
Keyword(s):  
Prostate Cancer ◽  
Risk Classification

Genomic validation of three-tiered sub-classification of high-risk prostate cancer.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 17-17
Author(s):  
Vinayak Muralidhar ◽  
Jingbin Zhang ◽  
Daniel Eidelberg Spratt ◽  
Felix Y Feng ◽  
Elai Davicioni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Intermediate Risk ◽  
High Risk Prostate Cancer ◽  
High Risk Disease ◽  
Genomic Markers ◽  
Risk Prostate Cancer ◽  
Clinical Genomic ◽  
Very High

17 Background: Recent data and National Comprehensive Cancer Network (NCCN) guidelines suggest that high-risk prostate cancer (cT3-4, Gleason score ≥ 8, or prostate-specific antigen [PSA] > 20 ng/mL) is a heterogenous group in terms of long-term patient outcomes. We sought to determine whether sub-classification of high-risk prostate cancer based on clinical factors correlates with genomic markers of risk. Methods: We identified 3,220 patients with NCCN unfavorable intermediate-risk (n=2,000) or high-risk (n=1,220) prostate cancer. We defined the following sub-classification of high-risk prostate cancer based on previously published data: favorable high-risk (cT1c, Gleason 6, and PSA > 20 ng/mL or cT1c, Gleason 4+4=8, PSA < 10 ng/mL); very high-risk (cT3b-T4 or primary Gleason pattern 5); and standard high-risk (all others with cT3a, Gleason score ≥ 8, or PSA > 20 ng/mL). We used a set of 37 previously published genomic classifiers, including the 22-gene Decipher assay, to determine whether high-risk genomic features correlated with the clinical sub-classification of high-risk prostate cancer. Results: Among those with favorable high-risk, standard high-risk, and very high-risk prostate cancer, 50.4%, 64.2%, 81.6% had a high-risk Decipher score, respectively (p < 0.001). Among 36 other genomic signatures, 33 had a similar increasing trend across the three sub-classes of high-risk (p < 0.05 after correction for multiple hypothesis testing). Patients in the three sub-classes of high-risk disease were positive for a median number of 5, 7, and 14 high-risk signatures. Under a novel clinical-genomic risk group classification (Spratt et al., 2017), 27.5%, 19.7%, and 7.0% of patients with favorable, standard, or very high-risk disease would be re-classified as intermediate-risk, respectively. In comparison, among those with unfavorable intermediate-risk prostate cancer, 38.2% had a high-risk Decipher score and would be re-classified as clinical-genomic high-risk. Conclusions: Genomic markers of risk correlate with the clinical sub-classification of high-risk prostate cancer into favorable high-risk, standard high-risk, and very high-risk disease, validating the prognostic utility of this stratification.

UP-02.070 Efficacy of Estramustine Phosphate according to Risk Classification of Castration-Resistant Prostate Cancer

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S283-S284
Author(s):  
A. Minato ◽  
N. Fujimoto ◽  
T. Kubo ◽  
S. Harada ◽  
S. Akasaka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Classification ◽  
Estramustine Phosphate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution

2020 ◽  
Vol 10 (1) ◽  
pp. 110
Author(s):  
Viktória Temesfői ◽  
Róbert Herczeg ◽  
Zoltán Lőcsei ◽  
Klára Sebestyén ◽  
Zsolt Sebestyén ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Risk Classification ◽  
Intermediate Risk ◽  
Risk Population ◽  
Intermediate Group ◽  
Risk Patients ◽  
The Impact ◽  
Radiotherapy Treatment ◽  
Hormone Deprivation

Background: Radiation therapy has undergone significant technical development in the past decade. However, the complex therapy of intermediate-risk patients with organ-confined prostate carcinoma still poses many questions. Our retrospective study investigated the impact of selected components of the treatment process including radiotherapy, hormone deprivation, risk classification, and patients’ response to therapy. Methods: The impact of delivered dose, planning accuracy, duration of hormone deprivation, risk classification, and the time to reach prostate-specific antigen (PSA) nadir state were analyzed among ninety-nine individuals afflicted with organ-confined disease. Progression was defined as a radiological or biochemical relapse within five years from radiotherapy treatment. Results: We found that 58.3% of the progressive population consisted of intermediate-risk patients. The progression rate in the intermediate group was higher (21.9%) than in the high-risk population (12.1%). Dividing the intermediate group, according to the International Society of Urological Pathology (ISUP) recommendations, resulted in the non-favorable subgroup having the highest rate of progression (33.3%) and depicting the lowest percentage of progression-free survival (66.7%). Conclusion: Extended pelvic irradiation on the regional lymph nodes may be necessary for the ISUP Grade 3 subgroup, similarly to the high-risk treatment. Therapy optimization regarding the intermediate-risk population based on the ISUP subgrouping suggestions is highly recommended in the treatment of organ-confined prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document